Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study by Surial, Bernard et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2020
Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected
Individuals With Renal Dysfunction-A Prospective Cohort Study
Surial, Bernard ; Béguelin, Charles ; Chave, Jean-Philippe ; Stöckle, Marcel ; Boillat-Blanco, Noémie ;
Doco-Lecompte, Thanh ; Bernasconi, Enos ; Fehr, Jan ; Günthard, Huldrych F ; Schmid, Patrick ;
Walti, Laura N ; Furrer, Hansjakob ; Rauch, Andri ; Wandeler, Gilles ; Swiss HIV Cohort Study
Abstract: BACKGROUND Whereas tenofovir disoproxil fumarate (TDF) can lead to renal adverse
events, tenofovir alafenamide (TAF) has a more favorable renal safety profile. However, the impact of
replacing TDF with TAF on renal function and liver parameters among HIV/hepatitis B virus (HBV)-
coinfected individuals with renal dysfunction remains unclear. METHODS We included all participants
from the Swiss HIV Cohort Study with an HIV/HBV coinfection who switched from TDF to TAF
and had an estimated glomerular filtration rate (eGFR) <90 mL/min/1.73 m and a suppressed HIV
viral load (<200 cp/mL). We assessed changes in eGFR, urine protein-to-creatinine ratio, and alanine
aminotransferase (ALT) after 1 year using mixed-effect models with interrupted time series. RESULTS
Among 106 participants (15.1% women, median age 53 years), eGFR was 60-89 mL/min/1.73 m in 84
(79.2%) and <60 mL/min/1.73 m in 22 (20.8%) individuals at the time of switch. One year after the
switch from TDF to TAF, individuals with an eGFR between 60 and 89 mL/min/1.73 m experienced
increases in eGFR of 3.2 mL/min/1.73 m (95% confidence interval [CI] 1.2 to 5.2), whereas those with
an eGFR <60 mL/min/1.73 m experienced improvements of 6.2 mL/min/1.73 m (95% CI 2.4 to 10.0).
Urine protein-to-creatinine ratio decreased overall (-6.3 mg/mmol, 95% CI -10.0 to -2.7), and ALT levels
declined in patients with elevated baseline levels (-11.8 IU/L, 95% CI -17.3 to -6.4) 1 year after replacing
TDF with TAF. CONCLUSIONS Switching from TDF to TAF among HIV/HBV-coinfected individuals
with renal impairment led to improvements in eGFR, a decline in proteinuria, and to ALT normalization
in those with elevated ALT levels.
DOI: https://doi.org/10.1097/QAI.0000000000002429
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-191820
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives
4.0 International (CC BY-NC-ND 4.0) License.
Originally published at:
Surial, Bernard; Béguelin, Charles; Chave, Jean-Philippe; Stöckle, Marcel; Boillat-Blanco, Noémie; Doco-
Lecompte, Thanh; Bernasconi, Enos; Fehr, Jan; Günthard, Huldrych F; Schmid, Patrick; Walti, Laura
N; Furrer, Hansjakob; Rauch, Andri; Wandeler, Gilles; Swiss HIV Cohort Study (2020). Brief Report:
Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective
Cohort Study. Journal of Acquired Immune Deficiency Syndromes, 85(2):227-232.
DOI: https://doi.org/10.1097/QAI.0000000000002429
2
BRIEF REPORT: CLINICAL SCIENCE
Switching From TDF to TAF in HIV/HBV-Coinfected
Individuals With Renal Dysfunction—A Prospective Cohort
Study
Bernard Surial, MD,a Charles Béguelin, MD,a Jean-Philippe Chave, MD,b Marcel Stöckle, MD,c
Noémie Boillat-Blanco, MD,d Thanh Doco-Lecompte, MD,e Enos Bernasconi, MD,f Jan Fehr, MD,g
,h
Huldrych F. Günthard, MD,g
,i Patrick Schmid, MD,j Laura N. Walti, MD,a Hansjakob Furrer, MD,a
Andri Rauch, MD,a Gilles Wandeler, MD,a
,k and the Swiss HIV Cohort Study
Background: Whereas tenofovir disoproxil fumarate (TDF) can lead
to renal adverse events, tenofovir alafenamide (TAF) has a more favorable
renal safety profile. However, the impact of replacing TDF with TAF on
renal function and liver parameters among HIV/hepatitis B virus (HBV)-
coinfected individuals with renal dysfunction remains unclear.
Methods: We included all participants from the Swiss HIV Cohort
Study with an HIV/HBV coinfection who switched from TDF to
TAF and had an estimated glomerular filtration rate (eGFR) ,90
mL/min/1.73 m2 and a suppressed HIV viral load (,200 cp/mL).
We assessed changes in eGFR, urine protein-to-creatinine ratio, and
alanine aminotransferase (ALT) after 1 year using mixed-effect
models with interrupted time series.
Results: Among 106 participants (15.1% women, median age 53
years), eGFR was 60–89 mL/min/1.73 m2 in 84 (79.2%) and
,60 mL/min/1.73 m2 in 22 (20.8%) individuals at the time of
switch. One year after the switch from TDF to TAF, individuals
with an eGFR between 60 and 89 mL/min/1.73 m2 experienced
increases in eGFR of 3.2 mL/min/1.73 m2 (95% confidence
interval [CI] 1.2 to 5.2), whereas those with an eGFR ,60 mL/
min/1.73 m2 experienced improvements of 6.2 mL/min/1.73 m2
(95% CI 2.4 to 10.0). Urine protein-to-creatinine ratio decreased
overall (26.3 mg/mmol, 95% CI 210.0 to 22.7), and ALT
levels declined in patients with elevated baseline levels (211.8
IU/L, 95% CI 217.3 to 26.4) 1 year after replacing TDF
with TAF.
Conclusions: Switching from TDF to TAF among HIV/HBV-
coinfected individuals with renal impairment led to improvements in
eGFR, a decline in proteinuria, and to ALT normalization in those with
elevated ALT levels.
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INTRODUCTION
Tenofovir-based antiretroviral therapy (ART) is the
mainstay of treatment for HIV/hepatitis B virus (HBV)
coinfection. Whereas resistance to lamivudine develops in a
significant proportion of HBV-infected individuals, HBV
resistance to tenofovir is rare.1 In addition, liver fibrosis
seems to improve with the use of tenofovir, and its use is
associated with a reduced incidence of cirrhosis and hepato-
cellular carcinoma.2–4
However, tenofovir disoproxil fumarate (TDF) has been
associated with renal side effects, such as proximal renal
tubulopathy.5 Moreover HBV infection itself can lead to
glomerular and tubular renal injury and, rarely, to the
development of end-stage renal disease.6 Tenofovir alafena-
mide (TAF) is a prodrug with a favorable renal safety profile
compared with TDF mainly because tenofovir plasma
concentrations are reduced by approximately 90%.7,8 Because
the studies that confirmed the renal safety of TAF in HIV/
HBV-infected individuals mainly enrolled individuals with-
out renal impairment,7,9 we evaluated the impact of replacing
TDF with TAF on estimated glomerular filtration rate
(eGFR), urine protein-to-creatinine ratio, and alanine amino-
transferase (ALT) levels in HIV/HBV-coinfected individuals
with renal dysfunction using data from the Swiss HIV Cohort
Study (SHCS).
METHODS
Study Design and Population
This multicenter prospective cohort study included all
HIV/HBV-coinfected individuals with an eGFR below 90
mL/min/1.73 m2, who had TDF replaced by TAF. The SHCS
(www.shcs.ch) is a national cohort that enrolls close to 80%
of all adults living with HIV currently receiving ART in
Switzerland.10 All data including laboratory measurements,
changes in ART, and co-administered medications are
recorded prospectively at enrollment and every 6 months
thereafter. Eligible participants were 18 years or older, had a
positive hepatitis B surface antigen (HBsAg) or detectable
HBV DNA, a suppressed HIV viral load (,200 cp/mL), were
on a TDF-containing ART regimen for at least 6 months, and
had an eGFR below 90 mL/min/1.73 m2. Pregnant women
and individuals with decompensated liver cirrhosis were
excluded. Data were collected between January 2014 and
February 2020. Local ethical committees of all cohort centers
approved this study, and all patients provided written
informed consent.
Outcomes and Definitions
Primary outcomes were changes in eGFR [calculated using
the chronic kidney disease epidemiology collaboration (CKD-
EPI) formula11] and urine protein-to-creatinine ratio (normal,15
mg/mmol) in the year before and the year after switch from TDF
to TAF. Secondary outcomes were HBV and HIV suppression
and HBsAg loss 1 year after the switch, as well as changes in
serum ALT in the year before and the year after the switch. We
considered all data collected at protocol-defined follow-up visits
within 2 years before and 18 months after switching to TAF.
Normal ALT levels were defined as #25 IU/L for women and
#35 IU/L for men.12 Liver fibrosis was assessed using transient
elastography (TE) or aspartate aminotransferase-to-platelet ratio
index (APRI) if TE was unavailable. Significant fibrosis was
defined as liver stiffness .7.0 kPa or APRI .1.5, and cirrhosis
as liver stiffness .11.0 kPa or APRI .2.0. Diabetes mellitus
was defined as HbA1c $6.5% or current antidiabetic treatment,
hepatitis C virus infection (HCV) as having a detectable HCV
viral load before switch, and hepatitis D virus (HDV) coinfection
as having a positive HDV serology. Hazardous alcohol use was
assessed using the Alcohol Use Disorders Identification Test
Consumption score and defined as $3 points in women and $4
points in men.13
Statistical Analysis
Baseline characteristics were presented using descriptive
statistics, and Fisher exact test or Wilcoxon rank sum tests
were used for group wise comparisons. Correlation coefficients
were calculated using Spearman’s rank correlation coefficient.
We used linear mixed-effect models with interrupted time
series to compare changes in eGFR, urine protein-to-creatinine
ratio, and ALT levels between the year before and the year
after the switch to TAF.14 Analyses for eGFR and urine
protein-to-creatinine ratio were adjusted for baseline age, sex,
ethnicity, diabetes, and treatment for arterial hypertension. Use
of integrase inhibitors, atazanavir, lopinavir, rilpivirine, cobici-
stat, and cotrimoxazole were added as time-varying covariates
in renal analyses to account for their potential impact on eGFR.
Urine protein-to-creatinine ratio analyses were further adjusted
for eGFR at baseline. Analyses of ALT changes were adjusted
for baseline age, sex, body mass index, HIV transmission
group (persons who inject drugs, men who have sex with men,
and others), HCV infection, and HBV replication status. In the
latter analysis, hazardous alcohol consumption and the use of
efavirenz (EFV) were included as time-varying covariates. All
analyses were performed using R version 3.6.2.
RESULTS
Study Population
Of 466 individuals with a positive HBsAg and active
follow-up, 224 switched from TDF to TAF. After excluding 8
individuals with a HIV viral load above 200 cp/mL and 110
individuals with an eGFR $90 mL/min/1.73 m2, 106
individuals formed the study population. Sixteen (15.1%)
participants were women, 20 (18.9%) were of African origin,
and the median age was 53 years (interquartile range [IQR]
48–58, Table 1). Baseline eGFR was between 60 and 89 mL/
min/1.73 m2 in 84 (79.2%) and below 60 mL/min/1.73 m2 in
22 (20.8%) individuals. Patients with an eGFR below 60 mL/
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min/1.73 m2 were older, more likely to receive a treatment for
arterial hypertension, and had lower CD4 cell counts and
higher urinary protein-to-creatinine ratios compared with
individuals with an eGFR of 60–89 mL/min/1.73 m2. The
median follow-up time on TAF was similar between both
groups [14.6 months (IQR 12.5–16.2) in individuals with an
eGFR of 60–89 mL/min/1.73 m2, and 14.1 months (IQR
12.4–16.9) in those with an eGFR below 60 mL/min/
1.73 m2]. Sixty-three patients (59.4%) had only TDF replaced
by TAF, the rest of the ART regimen remaining unchanged.
The most common reasons for stopping TDF were the
prevention of toxicity (37.1%), established renal toxicity
(17.1%), and treatment simplification (11.4%).
Changes in eGFR and Urine Protein-To-
Creatinine Ratio
Adjusted mean changes in eGFR are shown in the Figure
1A. Individuals with an eGFR between 60 and 89 mL/min/
1.73 m2 experienced changes in eGFR of 21.9 mL/min/
1.73 m2 in the last year on TDF [95% confidence interval (CI)
23.3 to 20.5], which increased to 3.2 mL/min/1.73 m2 1 year
(95% CI 1.2 to 5.2) after switching to TAF (P value for slope
difference 0.001). The use of TDF in individuals with an eGFR
below 60 mL/min/1.73 m2 led to a decline in eGFR (24.9
mL/min/1.73 m2 in the year before switch, 95% CI 27.5 to
22.2), and switching to TAF was associated with improve-
ments in eGFR (6.2 mL/min/1.73 m2 1 year after the switch,
95% CI 2.4 to 10.0, P value for slope difference ,0.001).
One year after switching to TAF, 58 (54.7%) individuals
had urine protein-to-creatinine ratio values available, and the
main demographic and clinical characteristics, including eGFR
at baseline, were similar between the group with and without
follow-up data. After adjusting for covariates, the use of TDF
was associated with a change in urine protein-to-creatinine ratio
of 0.9 mg/mmol in the last year before switch (95% CI 22.5 to
4.3), and switching to TAF led to a change in urine protein-to-
creatinine ratio of 26.3 mg/mmol 1 year after the switch (95%
CI 210.0 to 22.7, P-value for slope difference 0.01). Changes
in urine protein-to-creatinine ratio after 1 year did not correlate
with changes in eGFR over the course of time (correlation
coefficient 20.02, P = 0.91). Our findings on eGFR and urine
protein-to-creatinine ratio remained similar after restricting the
analyses to individuals who had the replacement of TDF by
TAF as the only ART change (see Table S1, Supplimental
Digital Content, http://links.lww.com/QAI/B499).
HIV and HBV Outcomes and Changes in
ALT Levels
One year after switching from TDF to TAF, 97 of 98
(99.0%) individuals with available HIV RNA follow-up
measurements had a suppressed viral load (,200 cp/mL).
The HBV viral load was suppressed (,50 IU/mL) in 64 of 66
(97.0%) individuals with available follow-up measurements.
One individual with detectable HIV and HBV viral loads
reported suboptimal adherence, and the other individual with
detectable HBV DNA did not have a suppressed HBV viral
load at the time of switch. HBsAg loss was observed in 4
(8.7%) of the 42 individuals with HBsAg measurements
available 1 year after switching to TAF.
Thirty-six individuals (34.0%) had elevated ALT levels
at baseline, 14 (13.2%) had significant fibrosis, and 6 (5.7%)
had liver cirrhosis. Among those with elevated ALT levels,
one individual (4.2%) had a detectable HBV viral load at
baseline, compared with 3 (4.2%) among those with normal
ALT levels. In adjusted analyses individuals with normal
ALT levels at baseline experienced ALT changes of 21.3
IU/L (95% CI 23.8 to 1.2) in the year before and of 20.1
IU/L (95% CI23.6 to 3.5) in the year after switching to TAF.
In individuals with elevated ALT levels, the use of TDF was
associated with increases in ALT of 5.9 IU/L per year (95%
CI 2.1 to 9.8), whereas they experienced marked decreases of
211.8 IU/L per year (95% CI217.3 to26.4) after the switch
to TAF (Fig. 1B). EFV was the third drug used in 5
individuals (7.1%) with normal ALT levels and in 6
individuals (16.6%) with elevated ALT levels at baseline.
In addition to switching to TAF, all but one of them received
a non-EFV containing regimen. Restricting the analyses to
individuals without EFV use or to individuals who only had
TDF replaced by TAF did not change our findings (see Table
S2, Supplemental Digital Content, http://links.lww.com/QAI/
B499).
DISCUSSION
In our nationwide cohort, switching from TDF to
TAF in HIV/HBV-coinfected individuals with renal dys-
function was associated with improvements in eGFR and
urinary protein-to-creatinine ratio and led to the mainte-
nance of HIV and HBV viral suppression. In addition,
patients with elevated ALT levels experienced significant
ALT reductions after switching to TAF. These findings
provide strong evidence of the benefits of replacing TDF by
TAF in HIV/HBV-coinfected patients with moderate
renal dysfunction.
In line with results from previous interventional
studies we found high HBV suppression rates 1 year after
starting TAF.7,9 However, earlier studies included mostly
individuals with normal renal function and showed modest
improvements in eGFR or a lower rate of decline with the
use of TAF when compared with TDF.7 In this study
switching to TAF was associated with improvements in
renal function, which was most pronounced in individuals
with a baseline eGFR below 60 mL/min/1.73 m2. Changes
in eGFR were not correlated with improvements in urinary
protein-to-creatinine ratios because switching from TDF to
TAF led to reductions in proteinuria irrespective of the
eGFR at baseline.
One third of our study population had elevated ALT
levels at baseline, and the replacement of TDF with TAF was
associated with a reduction in ALT levels in this subpopu-
lation, independent of other risk factors. For instance, the
association remained similar after excluding individuals on
EFV-based ART and after restricting the analysis to individ-
uals who had TDF replaced by TAF without further
modifications in their ART regimen. In registrational trials,
TAF was associated with faster rates of ALT normalization
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compared with TDF in HBV-monoinfected and HIV/HBV-
coinfected patients.7,9 However, as all but one individual had
a suppressed HBV viral load at baseline in our study, more
efficient HBV suppression cannot explain our results. Alto-
gether, these findings raise the possibility that TDF may cause
some degree of liver toxicity, which seems to be at least
partially reversible after switching to TAF. The potential for
liver toxicity of TDF has been observed in a large cohort
study of HIV-monoinfected individuals, which found a strong
relationship between TDF and elevated transaminases.15
Further studies are needed to confirm our finding and generate
potential explanations.
Our study is among the first to evaluate the benefit of
using TAF among HIV/HBV-coinfected individuals with
renal dysfunction. The use of interrupted time series allowed
us to compare dynamic changes in outcomes between the year
before and after the switch, whereas minimizing confounding
by variables that remain constant over the course of time.14
Although selection bias or confounding by indication is
possible in cohort studies, we were able to include most
patients in all analyses, except in the one focusing on urinary
protein-to-creatinine ratio. However, as the main demo-
graphic and clinical characteristics of individuals with and
without available proteinuria follow-up measurements did not
differ significantly, our results remain valid. The robustness
of the ALT analyses is challenged by the low number of
individuals with elevated levels at baseline, the brief follow-
up period of 1 year, and the possibility of a regression to the
mean effect. Finally, given that paired baseline and follow-up
TE measurements were unavailable for most individuals, the
analyses on ALT levels could not be stratified by the
underlying degree of fibrosis.
TABLE 1. Characteristics of the Study Population at the Time of Switch From TDF to TAF
eGFR 60–89 mL/min (n = 84) eGFR Below ,60 mL/min (n = 22) P
Female (%) 13 (15.5) 3 (13.6) 1.00
Median age in years (IQR) 51.5 (48–57) 54.5 (50.3–69.8) 0.02
African origin (%) 17 (20.2) 3 (13.6) 0.69
PWID (%) 4 (4.8) 2 (9.1) 0.60
Median CD4 count (cells/mL) 593 (426–806) 462.5 (274.3–636.3) 0.04
Hepatitis D infection (%) 5 (6.0) 2 (9.1) 0.96
Chronic HCV infection (%) 2 (2.4) 2 (9.1) 0.40
Diabetes (%) 5 (6.0) 3 (13.6) 0.45
Treated for arterial hypertension (%) 23 (27.4) 12 (54.5) 0.03
Median eGFR in mL/min (IQR) 78.2 (71.3–83.8) 53.0 (47.5–55.2) ,0.001
Median urine protein-to-creatinine ratio in mg/mmol
(IQR)
11.5 (8.8–18.1) 21.4 (15.9–64.4) 0.01
Urine protein-to-creatinine ratio (%) 0.01
.50 mg/mmol 4 (4.8) 5 (22.7)
Missing 23 (27.4) 5 (22.7)
Median ALT in IU/L (IQR) 27.0 (20.5–38.3) 23.0 (17.0–38.0) 0.23
ALT elevated* (%) 30 (35.7) 6 (27.3) 0.82
Grade 1 (,2.5 ULN, %) 28 (33.3) 6 (27.3)
Grade 2 ($2.5 to ,5 times ULN, %) 1 (1.2) 0
Grade 3 ($5 to ,10 times ULN, %) 1 (1.2) 0
Grade 4 ($10 times ULN, %) 0 0
Significant fibrosis† (%) 13 (15.5) 1 (4.5) 0.29
Cirrhosis‡ (%) 6 (7.1) 0 0.34
Median time on TDF in years (IQR) 10.2 (6.5–12.2) 11.4 (9.2–14.5) 0.11
Switch from TDF to TAF without changes in other
components (%)
48 (57.1) 15 (68.2) 0.49
Third drug before switch (%) 0.27
Dolutegravir 16 (19.0) 6 (27.3)
Rilpivirine 12 (14.3) 6 (27.3)
Darunavir 11 (13.1) 4 (18.2)
Elvitegravir 10 (11.9) 0
Efavirenz 10 (11.9) 1 (4.5)
Others 25 (29.8) 5 (22.7)
HCV, hepatitis C virus; eGFR, estimated glomerular filtration rate; PWID, persons who inject drugs, ULN, upper limit of normal.
*ALT .25 for women and .35 for men, according to recommendations of the American Association for the Study of Liver Diseases (AASLD).
†TE .7.0 kPa or APRI .1.5.
‡TE .11.0 kPa or APRI . 2.0.
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CONCLUSIONS
Switching from TDF to TAF among HIV/HBV-
coinfected individuals with renal impairment led to improve-
ments in eGFR, a decline in proteinuria, and to ALT
normalization in those with elevated ALT levels. The use of
TAF in those individuals seems to be safe and effective, and
switching from TDF to TAF should be considered among
coinfected individuals with renal impairment or with other-
wise unexplained ALT elevations.
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(Chairman of the Scientific Board), Rudin C, Scherrer AU
(Head of Data Centre), Schmid P, Speck R, Stöckle M
(Chairman of the Clinical and Laboratory Committee), Tarr
P, Trkola A, Vernazza P, Wandeler G, Weber R, and Yerly S.
The data are gathered by the Five Swiss University
Hospitals, two Cantonal Hospitals, 15 affiliated hospitals and
36 private physicians (listed in http://www.shcs.ch/180-
health-care-providers).
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